Aspire Biopharma, Inc. Announces Newly Appointed Board of Directors Members

HUMACAO, PR, May 25, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the election results and appointment of two new Board of Directors members effective Thursday, May 25, 2023.

On Thursday, May 25, 2023, the shareholders of Aspire Biopharma, Inc., in a unanimous vote, elected two new members to its Board of Directors. The biographical information on each of the newly appointed Board Members can be found on the Company’s website in the investor relations


Kraig Higginson, Executive Chairman, stated, “On behalf of the new members of the Board, Roderic Prat and Ernest Scheidemann, we’d like to thank the shareholders for their support. It is the intent of the newly elected Board of Directors and Aspire’s management team to build enduring shareholder value and to communicate with our shareholders on a regular basis.”

About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit

Safe Harbor Statement. Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Aspire Biopharma, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward- looking statements can be found in the Company’s Form CF and Form D, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether because of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.